Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Figure 5
Percentage of patients with 20/40 or better vision over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively. ANCHOR: at month 0; SAILOR cohort 1 treatment-naïve: at month 0.
